Ameresco (AMRC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
Acacia Communications, Inc. (ACIA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
Looking at the universe of stocks we cover at Dividend Channel, on 12/31/20, Federal Realty Investment Trust (Symbol: FRT), State Street Corp. (Symbol: STT), and CyrusOne Inc (Symbol: CONE) will all trade ex-dividend for their respective upcoming dividends. Federal Realty Inv
Looking at the universe of stocks we cover at Dividend Channel, on 12/31/20, American Homes 4 Rent (Symbol: AMH), CubeSmart (Symbol: CUBE), and Essex Property Trust Inc (Symbol: ESS) will all trade ex-dividend for their respective upcoming dividends. American Homes 4 Rent will
Looking at the universe of stocks we cover at Dividend Channel, on 12/31/20, Encompass Health Corp (Symbol: EHC), Washington Trust Bancorp, Inc. (Symbol: WASH), and Ventas Inc (Symbol: VTR) will all trade ex-dividend for their respective upcoming dividends. Encompass Health Co
Looking at the universe of stocks we cover at Dividend Channel, on 12/31/20, Equity Residential (Symbol: EQR), Cousins Properties Inc (Symbol: CUZ), and Quanta Services, Inc. (Symbol: PWR) will all trade ex-dividend for their respective upcoming dividends. Equity Residential w
A look at the weighted underlying holdings of the ProShares ProShares DJ Brookfield Global Infrastructure ETF (TOLZ) shows an impressive 10.7% of holdings on a weighted basis have experienced insider buying within the past six months.
Enterprise Products Partners L.P. (Symbol:
A look at the weighted underlying holdings of the First Trust Materials AlphaDEX Fund (FXZ) shows an impressive 13.4% of holdings on a weighted basis have experienced insider buying within the past six months.
Element Solutions Inc (Symbol: ESI), which makes up 5.07% of the Fi
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?One w
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
Shares of Tesla, Inc. TSLA rose 0.3% following news that the company is planning to start its operations in India next year.Lockheed Martin Corp. LMT shares gained 0.6% after the company said that it delivered 123 F-35 fighter jets to the U.S. and its allies in 2020, meeting the
One stock that might be an intriguing choice for investors right now is Cross Country Healthcare, Inc. CCRN. This is because this security in the Staffing Firms space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspecti
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
The year 2020 has been great for FAANG stocks. While returns from Alphabet GOOGL have been disappointing, Apple AAPL, Amazon AMZN, Netflix NFLX and Facebook FB have had an impressive run on the bourses.The group has benefited from strong demand for e-commerce services and increas
The drug/biotech sector has delivered on investor expectations by making medicines/vaccines for COVID-19 in record time. Rapid development and regulatory approvals of some medicines and vaccines put the drug/biotech sector back on track after companies reported soft third-quarter
If you're making buy decisions based on the daily gyrations of the S&P 500, you're setting yourself up for big losses--and costing yourself a shot at big dividends, too.
Britain's trade agreement with the European Union removes a 4-1/2-year old fear of crashing out of the bloc without trading arrangements in place, but it will take UK financial markets years to lose their Brexit-inflicted scars.
Shares of Myovant Sciences surged 20.5% after the biopharma company announced a collaboration with Pfizer (PFE) to jointly develop and commercialize ORGOVYX – a drug for the treatment of prostate cancer and women's health disorders.
Per the deal “Myovant will receive up to $4.2 billion, including an upfront payment of $650 million, $200 million in potential regulatory milestones for US Food and Drug Administration (FDA) approvals for relugolix combination tablet in women’s health, and tiered sales milestones upon reaching certain thresholds up to $2.5 billion in net sales for prostate cancer and also for the combined women’s health indications.” (See MYOV stock analysis on TipRanks).
Myovant (MYOV) said that ORGOVYX has been approved by the FDA on Dec. 18 for treating adults with prostate cancer. The company noted that, “ORGOVYX is the first and only oral GnRH antagonist for men with advanced prostate cancer.”
Myovant CEO Lynn Seely said, “Pfizer is the ideal partner for Myovant given its impressive capabilities and track record across both oncology and women’s health. This transformative collaboration will significantly strengthen the upcoming launch of ORGOVYX and the potential launches of relugolix combination tablet in women’s health, while substantially enhancing our financial position and enabling us to expand our pipeline of potential new medicines.”
Following the announcement, Goldman Sachs analyst Paul Choi reiterated a Buy rating and the price target of $30 (9.5% upside potential). Choi believes that the deal is “a positive strategic step” that should ease investors’ concern about its ability to self-commercialize the drug.
The analyst said that the deal terms are attractive, and collaboration with a larger partner should improve the commercial outlook of ORGOVYX.
The rest of the Street echoes Choi's bullish sentiment, with a Strong Buy analyst consensus based on 6 unanimous Buys. With its shares down about 77% this year, the average price target of $36.17 suggests upside potential of about 32% to current levels.
Tesla will start selling electric vehicles (EV) in India early next year, Nitin Gadkari, the country’s transport minister confirmed during an interview with The Indian Express newspaper.
The minister disclosed that Tesla (TSLA) will begin its operations with sales in the Indian market and then maybe look for assembly and manufacturing facilities.
Last week, ETAuto.com reported that the first model to be launched in India could be the Model 3 Sedan, the cheapest among Tesla vehicles. The bookings may start in January, according to ETAuto.com. (See TSLA stock analysis on TipRanks)
Replying to a tweet, Tesla CEO, Elon Musk, said on Sunday that the company plans to enter the Indian market in 2021 but it is not happening in January.
On Dec. 21, Wedbush analyst Daniel Ives raised the stock’s price target to $715 (7.7% upside potential) from $560 and reiterated a Hold rating.
In a note to investors, Ives wrote “Heading into year-end and 2021, we are seeing a major inflection of EV demand globally with our expectations that EV vehicles ramp from ~3% of total auto sales today to 10% by 2025. We believe this demand dynamic will disproportionately benefit the clear EV category leader Tesla over the next few years especially in the key China region which we believe could represent ~40% of its EV deliveries by 2022 given the current brisk pace of sales.”
Meanwhile, the consensus among analysts is a Hold based on 11 Holds, 7 Buys and 7 Sells. With shares skyrocketing 693.3% year-to-date, the average price target of $455.22 implies downside potential of about 31.4% to current levels.